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ABSTRACT
The leaf extract of Ginkgo biloba has purported value for improving mental capacities in Alzheimer’s patients. The flavonols
and the terpene lactones are considered to be the two major groups of active components that influence human health. Almost all
the clinical studies regarding G. Biloba were using either EGb 761®, a proprietary extract of G. Biloba leaves, or an extract prepared
according to the standard set by it. Consequently, most of the commercial G. Biloba products were labeled with their content
accordingly. This paper studied the compositions of both flavonols and terpene lactones of seven commercially available G.
Biloba products and three standard reference materials (SRM 3246 G. Biloba leaves, SRM 3247 G. Biloba extract, and SRM 3248
G. Biloba tablet) from the National Institute of Standards and Technology (NIST). In this study, a chromatographic method with
UV and mass spectroscopic detection was employed for the determination of the compositions of flavonols and the terpene lactones
in Ginkgo products using gradient reversed-phase HPLC. Methanol-water (1:1) extracts of terpene lactones and flavonols out of G.
Biloba products and NIST SRMs were analyzed qualitatively and quantitatively. While the relative compositions of the flavonol
glycosides were similar for the NIST SRMs, those for the commercial G. Biloba products varied significantly. The relative concentrations of terpene lactones were also shown significant differences among products, but not as dramatic as that of flavonols.
Key words: Ginkgo biloba, HPLC, UV, MS, flavonols, terpene lactones

INTRODUCTION
The Ginkgo biloba tree is one of the oldest known
trees on earth with fossil records dating back more than
200 million years. Extracts from the G. Biloba leaves
(GBE) have long been used in China as a traditional
medicine for various ailments. Scientific studies of G.
Biloba began in the 1950s and have shown it to be a
useful remedy for a wide range of disorders (1). Ginkgo
has been reported to inf luence fundamental aspects of
human physiology in two ways: (1) improving blood flow
to tissues including the brain, and (2) enhancing cellular
metabolism. Many of the illnesses relieved by GBE are
associated with old age, a time often linked to the deterioration of blood flow and cellular metabolism(2). Other
illnesses that may occur earlier in life also respond to
GBE, including asthma, tinnitus, vertigo, and impotence (2). A standardized Ginkgo biloba preparation, EGb
761®, is prescribed widely in Germany and France for
the treatment of a range of conditions, such as memory
and concentration problems, confusion, depression, anxiety, dizziness, tinnitus and headaches (3). EGb 761® is a
proprietary extract of Ginkgo biloba leaves established
by W. Schwabe Company (Karlsruhe, Germany). It is
a dried powder standardized to contain 24% ginkgo* Author for correspondence. Tel: +301-504-8144;
E-mail: chenp@ba.ars.usda.gov

f lavonol glycosides and 6% terpene lactones. The dry
extract is pharmaceutically prepared to a 35-67:1 ratio
of dried leaves to the final extract. A book reviewing
the chemistry, pharmacology, toxicology, and all clinical
studies conducted on EGb 761® in various areas of clinical application was published in 1998 (DeFeudis). Many
GBEs were usually prepared by following the standard
set by EGb 761®.
The pharmacological activities of GBE have been
attributed to two classes of compounds - terpene lactones
and flavonols (4). Terpene lactones are potent and selective antagonists of platelet activating factor. Flavonols
are responsible for the free radical scavenge and antioxidant activity of Ginkgo preparations (4). Quercetin,
kaempferol, and isorhamnetin are the aglycones of the
flavonols present in GBE (5,6). A few flavonol glycosides
have been identified in GBE (7).
Many methods have been developed for the determination of flavonols and terpene lactones, with separate
methods for each group. HPLC/UV is currently the most
popular system for flavonol determination. Flavonols are
quantified by converting to the aglycone forms through
acid hydrolysis (6) and comparing to the aglycone standards. Ginkgolides are poor chromopheres with weak
absorption in the range of 200-220 nm. This makes UV
detection an unsuitable option in a complex matrix (6).
Therefore, other detection methods, such as evaporative
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light scattering detection (ELSD), sonic spray ionization
(SSI) mass spectrometry, atmospheric pressure chemical
ionization (APCI) mass spectrometry, and electrospray
(ESI) mass spectrometry, have been used for the determination of the terpene lactones (8-12).
Currently, consumers must rely on the labels of G.
Biloba products for the information regarding the active
ingredients. Unfortunately, there is no guarantee that this
information is either accurate or adequate. Recently, the
National Institute for Standards and Technology (NIST)
has introduced standard reference materials (SRMs) for
G. Biloba. The availability of authentic G. Biloba SRMs
not only provides benchmarks for total terpene lactones
and total flavonols, but also for the compositions of the
flavonol glycosides and terpene lactones. In this study,
a LC/UV/MS method was used for the determination of
flavonol glycoside and terpene lactones composition. This
method was also used for the quantitation of flavonol aglycones following hydrolysis. Seven commercial G. Biloba
products and three G. Biloba references (SRM 3246 leaf
material, SRM 3247 dried extract, and SRM 3248 tablets)
from NIST were examined. The compositions of flavonols and terpene lactones of the commercial products
were compared to those of the NIST SRMs. Pure flavonol
and terpene lactone standards were used to quantify the
contents of the commercial products for the examination
of their label values.

MATERIALs AND METHODS
I. Commercial Samples
Seven different over-the-counter G. Biloba commercial samples (designated as sample A, B, C, D, E, F, and G)
were purchased from local stores for analysis. All seven
commercial samples were purchased within the same
week. Among these samples, five were in solid forms

(tablets and capsules) and two (F and G) were in liquid
form. Sample F was a suspension in 33.33% alcohol in
water and sample G was a suspension in 50% alcohol
in water. SRM 3246, SRM 3247, and SRM 3248 were
obtained from NIST.
II. Sample Preparation
The samples from seven commercial products (Table
1) were prepared as follows. Tablets were weighed and
grounded into fine powder using a mortar and pestle.
Capsules were opened and emptied, and the contents
were mixed. Two hundred milligrams of each solid
sample was weighed and transferred into a 15-mL centrifuge tube. H 2 O/MeOH (1:1) extraction was used to
extract flavonol glycosides and terpene lactones as it was
one of the preferred systems as discussed by van Beek(6).
Ten milliliter of H 2O/MeOH (1:1) was then added to each
centrifuge tube. For samples in liquid form, 400 µL of
samples were pipetted into 15-mL centrifuge tubes and
9.6 mL of H 2 O/MeOH (1:1) was added to each centrifuge tube. All samples were sonicated for 15 min and
centrifuged for 10 min at 1,500 rpm. The supernatant
was decanted into a 45-mL centrifuge tube. An additional extraction was performed in the same manner as
described above. The two extracts were combined and
filtered through Nylon 25 mm × 0.45 µm syringe filters
(Alltech Associate Inc., Deerfield, IL).
III. Chemicals
The water and methanol used were of Optima*
grade (Fisher Scientific, Pittsburgh, PA). The trif luoroacetic acid (TFA) used was of HPLC grade (Sigma/
Aldrich, St. Louis, MO). Bilobalide, ginkgolide A,
ginkgolide B, ginkgolide C, quercetin, kaempferol and
isorhamnetin were also purchased from Sigma; purities
were all labeled as greater than 90%.

Table 1. Labeled information of the investigated Gingko biloba commercial samples

a

Sample name

Form

GBE per tablet (mg)a

Daily intakeb

Flavonol glycosides
amount (mg)c,d

Ginkgolides amount
(mg)e

Sample A

Capsule

40

3×1

28.8

N/A

Sample B

Tablet

30

2×2

28.8

N/A

Sample C

Capsule

60

2×1

28.8

N/A

Sample D

Tablet

60

2×1

28.8

N/A

Sample E

Ccapsule

120

1×1

28.8

7.2

Sample F

Liquid

N/A

1 - 3 mL

N/A

N/A

Sample G

Liquid

N/A

1 - 3 mL

N/A

N/A

The amount of the G. Biloba Extract (GBE) labeled per tablet/capsule where applicable.
b
Daily repetitions × number of tablets/capsules/mL recommended by the manufactures.
c
The total labeled amount of flavonol glycosides in daily dosage.
d
The total flavonol glycosides contents in all commercial samples are incorrectly labeled as “flavone glycosides”.
e
The total labeled amount of ginkgolides in daily dosage.
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IV. Acid Hydrolysis
Flavonol glycosides were converted to their aglycones by acid hydrolysis before quantitation, by following the method repor ted by Wag ner (13) with slight
modification (volume of 1 mL instead of 10 mL). The
hydrolysis was carried by adding 1 mL of 5.5% HCl in
MeOH to 1 mL aliquot of G. Biloba extract in a closed
flask; the resulting solution was heated for 1 hr at 100°C.
Five hundred microliter of the hydrolyzed samples were
immediately transferred into standard a 2-mL HPLC
vials and analyzed.
V. Instrumentation and the LC/UV/MS Method
A n Agilent 1100 HPLC system consisting of a
binary pump with a vacuum degasser, a thermostatted
column compartment, an auto-sampler, and a diode array
detector (DAD, Agilent Technologies, Palo Alto, CA)
was used in combination with a LCQ Classic ion-trap
mass spectrometer controlled by Xcalibur software
(Thermo/Finnigan, San Jose, CA). A Supelco Discovery C18 HPLC column (250 × 3.0 mm, 5 µm) was used
(Sigma/Aldrich, St. Louis, MO) for the LC/ U V/ MS
method.
The HPLC conditions for the LC/UV/MS method
were optimized after screening a number of solvent
systems with different gradient elution profiles. The
final method was a modified one from Li’s method (8).
The original method was developed for the separation of
terpene lactones and flavonol aglycones. The modification included a different gradient profile to accommodate the separation of flavonol glycosides and the use of
a narrow bore column with lower flow rate to optimize
mass spectrometric detection. Mobile phase A consisted
of 0.05% TFA in H 2O and mobile phase B consisted of
0.05% TFA in MeOH. The gradient profile is listed in
Table 2. The wavelength for UV detection was 370 nm.
The parameters of the mass spectrometer were optimized
by direct infusion of bilobalide using the auto-tuning
routine of the LC/UV/MS system. The following conditions were used: positive ion mode, vaporizer temperature, 400°C; sheath gas f low rate, 70 (arbitrary units);
Table 2. The HPLC gradient profile of the LC/UV/MS method
Time
(min)

Mobile phase A
0.05% TFA in H2O

Mobile phase B
0.05% TFA in MeOH

0.00

70.0 %

30.0 %

26.0

30.0 %

70.0 %

28.0

5.0 %

95.0 %

33.0

5.0 %

95.0 %

33.1

70.0 %

30.0 %

40.0

70.0 %

30.0 %

Flow rate was 0.500 mL/min

aux gas flow rate, 10 (arbitrary units); discharge current,
5.0 µA; heated capillary temperature, 200°C; capillary
voltage, -47.0 V; tube lens offset, 20 V. The conditions
gave satisfactory sensitivities for all the terpene lactones
and flavonol aglycones investigated.
For qualitative analyses, APCI in full MS scan mode
was used for the flavonol glycoside identification and the
integrated peak areas from UV absorption were used to
calculate the relative amount of individual flavonol glycoside. For quantitation, APCI in selected ion monitoring
mode (SIM) was used to quantify terpene lactones and the
UV absorption was used to quantify flavonol aglycones.
Both methods used the same HPLC system.
VI. Calculation
The limits of detection (LOD) were estimated at a
signal to noise ratio of 3 (S/N = 3). The limits of quantitation (LOQ) were estimated at a signal to noise ratio of
10 (S/N = 10).
The daily intake values of terpene lactones and flavonol
aglycones in tablet or capsule form of G. Biloba commercial samples were calculated from concentrations measured
by the LC/UV/MS method using the formula below.
DIV = (Cs × Wd × Dil × V)/1000Ws.
DIV = daily intake value (mg).
Cs

= measured concentration of analyte in hydrolyzed G. Biloba samples (µg/mL).
Wd = t otal weight of daily intake tablets or capsule
(mg).
Dil = d ilution factor. Samples diluted 2 folds in
hydrolysis and 5 folds before analysis.
V
= volume of sample extraction solution (mL).
Ws = weight of sample extracted, mg.
1000 = converting factor from µg to mg.
The daily dosages of terpene lactones and flavonol
aglycones in liquid G. Biloba samples were calculated
from their hydrolyzed solutions as below.
DIV = (Cs × Vd × Dil × V)/1000Vs.
DIV = daily intake value (mg).
Cs = m
 easured concentration of analyte in hydrolyzed G. Biloba samples (µg/mL).
Vd = total volume of daily intake suggested (mL).
Dil = d ilution factor. Samples diluted 2 folds in
hydrolysis and 5 folds before analysis.
V
= volume of sample extraction solution (mL).
Vs = volume of sample extracted (mL).
1000 = converting factor from µg to mg.
The quantities of total f lavonol glycosides were
calculated from the measured quantities of f lavonol
aglycones using a method described by Hasler (7). The
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RESULTS AND DISCUSSION
I. Sample Preparation
Several different extraction systems for terpene
lactones were described in detail in van Beek’s 2002
review(6). From the review, it was clear that the methanolwater (1:1) system was one of the preferred choices for
the ginkgolide extraction. To evaluate the effectiveness
of this solvent system for the extraction of flavonol glycosides, triple extractions were performed. Each extract
was analyzed individually by the LC/UV/MS system.
No detectable amount of f lavonol glycosides was found
in the third extract; therefore, two extractions were used
throughout the experiments. According to the product
labels, 400 µL of the liquid sample was roughly comparable to 200 mg of the solid samples in the recommended
daily dosage (not to be confused with the Recommended
Daily Allowance of the National Academy of Science;
there are no RDAs for flavonols or terpene lactones).
II. HPLC Method
The method used in this study was optimized for the
separation of terpene lactones and flavonol aglycones as
well as the separation of flavonol glycosides. Previously
reported methods (9-12) often concentrated on only one
separation mentioned above, but not both. Besides, the
other advantages of our method are shorter analysis time
and lower f low rate (saving solvent) compared to most
published methods. The low flow rate also offered better
sensitivity for the mass spectrometric detection.

LC/UV chromatograms of the extracts of two typical
commercial G. Biloba products and NIST SRM 3247 without hydrolysis are shown in Figure 1. The peak labeled
with the question mark, although appeared at 370 nm, was
not a f lavonol glycoside as MS study did not show any
f lavonol aglycone fragment. Ten major f lavonol peaks
from the NIST SRM 3247 were listed in Table 3. Nine
were identified by comparing the mass spectra and relative retention time with other published results (7,12,14).
Peak 4 was not identified despite our best effort. Peaks
one to ten were observed for all the samples investigated.
However, the percentile of each of flavonol glycoside peak
varied significantly among samples (Table 4, Figure 2).
The composition of the flavonol glycosides was evaluated
based on their percentiles, which were calculated by dividing individual integrated peak area by the sum of the areas

Relative absorbance

conversion rates are 2.51 for quercetin, 2.64 for kaempferol, and 2.39 for isorhamnetin.

RT: 8.00 - 19.50
100
80 Sample A
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0

NL:
1.21E4
Channel A
UV
sample-1-01

NL:
5.39E4
Channel A
UV
sample-3-03

Sample C

SRM 3247
1

8

9

10

?

2

11

3

12

13

4

5

6 7

14

15

16

8

17

9

10

18

NL:
8.62E3
Channel A
UV srm
3247-01

19

Time (min)

III. Qualitative Analysis and Composition of Flavonol
Glycosides

Figure 1. The LC/UV chromatograms (UV 370 nm) of the extracts
of commercial G. Biloba Sample A, Sample C, and the NIST SRM
3247 (the peak with the question mark is not a flavonol glycoside).

Table 3. Major flavonol glycosides identified in NIST SRM 3247
Peak number

m/z

Retention time

1

757

19.99

3-O-(2’’-O(6’’-O-bis(α-L-rhamnosyl)-β-D-glucosyl) quercetin

2

741

11.79

3-O-(2’’-O(6’’-O-bis(α-L-rhamnosyl)-β-D-glucosyl) kaempferol

3

611

13.37

3-O-(6’’-O-(α-L-rhamnosyl)-β-D-glucosyl) quercetin

4

641

14.23

Unidentified

5

611

15.21

3-O-(2-O-(β-D-glucosyl)-α-L-rhamnosyl) quercetin

6

595

15.91

3-O-(6’’-O-(α-L-rhamnosyl)-β-D-glucosyl) kaempferol

7

625

16.47

3-O-(6’’-O-(α-L-rhamnosyl)-β-D-glucosyl) isorhamnetin

8

757

16.90

3-O-(2’’-O(6’’’-O-(p-coumaroyl)-β-D-glucosyl)-α-L-rhamnosyl) quercetin

9

595

17.71

3-O-(2-O-(β-D-glucosyl)-α-L-rhamnosyl) kaempferol

10

741

19.20

3-O-(2’’-O(6’’’-O-(p-coumaroyl)-β-D-glucosyl)-α-L-rhamnosyl) kaempferol

Compound name
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The percentile of any peak (x) is calculated by divide the peak area of peak number x by the sum of peak areas of the ten peaks for any given sample.

of all ten major peaks. While the molar absorptivity and
wavelength of maximum absorbance may shift, depending
on the type of glycoside and the position of attachment, a
comparison of the percentiles can provide an estimate of
the ratios of individual flavonol glycoside among the total
flavonol glycosides. All three NIST reference materials
(leaf, extract, and tablet) have similar flavonol glycoside
compositions (Figure 2). This indicates that the extraction and tablet production procedures used by the NIST
did not change the flavonol glycoside profiles significantly.
Conversely, all the commercial samples had significantly
different flavonol glycoside composition compared with the
NIST SRMs and with each other. Some of the commercial products were closer to the NIST SRMs than others,
such as sample A (Figure 2). It is interesting that sample
C and sample E had significant larger portion of quercetin
3-O-rutinoside, also know as rutin, as compared to both
NIST SRMs and other commercial Ginkgo products.
IV. Quantitative Analysis
Quantitation of the flavonol glycosides by LC/UV was
very difficult due to the lack of commercially available
standards. Instead, the flavonol glycosides were converted
to their aglycone forms by acid hydrolysis, a well established procedure. Authentic standards for the three main
aglycones (quercetin, kaempferol, and isorhamnetin)
resulting from the hydrolysis are commercially available.
LC/UV/MS chromatograms of NIST SRM 3247 sample
is shown in Figure 3. The limits of detections (LOD), the
limits of quantitation (LOQ), the ranges, and the correlation coefficients (r 2) for ginkgolide A, ginkgolide B,
ginkgolide C, bilobalide, quercetin, kaempferol, and isorhamnetin are shown in Table 5. The terpene lactones were
quantified by APCI-MS, whereas, the flavonol aglycones
could be quantified by either UV detection or APCI-MS
detection. The UV quantitation of the flavonol aglycones
gave better linearity compared to that of MS (Table 5),
so the UV data were used. The results of the quantitative
analysis are shown in Table 6. The data were first demon-

100%

Relative peak area

14.63 ± 0.09
14.99 ± 0.06
12.93 ± 0.11
32.14 ± 0.41
12.52 ± 0.30
Sample G

19.72 ± 0.03

4.85 ± 0.09

2.94 ± 0.12

12.64 ± 0.02

2.64 ± 0.05
a

17.11 ± 0.09
13.60 ± 0.13
10.65 ± 0.05
13.62 ± 0.18
18.33 ± 0.16
Sample F

16.32 ± 0.06

4.51 ± 0.08

6.48 ± 0.03

14.32 ± 0.38

5.05 ± 0.10

14.64 ± 0.26

16.19 ± 0.21

16.47 ± 0.02
11.78 ± 0.06

3.17 ± 0.04

18.48 ± 0.08
18.13 ± 0.09

10.95 ± 0.03
4.70 ± 0.17
77.84 ± 0.49
10.21 ± 0.02

3.25 ± 0.11
50.23 ± 0.22
16.03 ± 0.06

10.14 ± 0.01
Sample E

Sample D

14.07 ± 0.10

0.10 ± 0.01

3.79 ± 0.07

16.27 ± 0.08

3.54 ± 0.05

12.35 ± 0.09
13.88 ± 0.09
12.12 ± 0.04
84.03 ± 0.14
10.85 ± 0.03
Sample C

10.66 ± 0.02

0.27 ± 0.02

2.68 ± 0.07

11.39 ± 0.03

1.76 ± 0.03

15.72 ± 0.02
17.69 ± 0.13
18.71 ± 0.16
50.44 ± 0.19
16.31 ± 0.01
Sample B

14.54 ± 0.06

3.49 ± 0.11

3.48 ± 0.15

16.41 ± 0.06

3.20 ± 0.15

17.46 ± 0.36
11.65 ± 0.46
19.07 ± 0.61
39.40 ± 0.32
16.42 ± 0.03
Sample A

14.87 ± 0.11

4.41 ± 0.07

5.69 ± 0.07

16.48 ± 0.08

4.55 ± 0.13

17.59 ± 0.08
12.18 ± 0.14
19.25 ± 0.11
26.66 ± 0.19
10.00 ± 0.02
SRM 3248

11.26 ± 0.07

5.07 ± 0.10

5.34 ± 0.16

18.77 ± 0.03

3.88 ± 0.12

17.29 ± 0.05
12.07 ± 0.39
19.25 ± 0.04
26.89 ± 0.20
10.07 ± 0.13
SRM 3247

11.32 ± 0.12

5.06 ± 0.04

5.22 ± 0.03

18.91 ± 0.21

3.92 ± 0.06

10.76 ± 0.07
13.48 ± 0.49
17.39 ± 0.14
26.40 ± 0.29
19.63 ± 0.24
SRM 3246

10.55 ± 0.18

4.77 ± 0.05

4.52 ± 0.14

18.52 ± 0.07

3.98 ± 0.06

19.20
17.71
16.90
16.47
13.37
Retention time (min)

9.99

11.79

14.23

15.21

15.91

8
4
3
2
1
Peak number

Table 4. Compositions of flavonol glycosides in G. Biloba products and NIST SRMs (n = 3)a

5

6

7

9

10

Journal of Food and Drug Analysis, Vol. 15, No. 1, 2007

Peak 10

80%

Peak 9
Peak 8

60%

Peak 7
Peak 6

40%

Peak 5
Peak 4
Peak 3

20%

Peak 2
Peak 1

0%

SRM SRM SRM S-a S-b
3246 3247 3248

S-c S-d S-e S-f

S-g

Figure 2. Flavonol glycoside composition in commercial G. Biloba
products and the NIST SRMs.
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strated in measured concentrations, followed by daily
intake values in order to have a better sample to sample
comparison since the weights of the tablets/capsules of the
samples were different. The measured and labeled total
amounts for terpene lactones and flavonol glycosides are
listed in Table 7. The total flavonol glycosides contents of
the samples were calculated from the flavonol aglycones as
described in the Method
G. Biloba extract in the daily dosage of 120 to
240 mg has been used in clinical trials and reported to
be effective (15-18). All the solid (tablets and capsules)
commercial products investigated in this study were
labeled their daily dosage equivalent to 120 mg of
GBE, or 28.8 mg of f lavonol glycosides (24% f lavonol
glycosides/GBE). Only sample E provided a value for
the terpene lactones content of 6% (m/m) or an intake

Relative abundance

RT: 5.00 - 25.00

NL:
100
9.24E7
GA
90
TIC M S
srm324880
GC
01
70
Kaempferol
60
GB
50
40
Isorhamnetin
Quercetin
30
20 Bilobalide
10
0
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

of 7.2 mg per day (Table 5). Qualitative and quantitative analysis of G. Biloba products by the LC/UV/MS
method demonstrated that there were differences in the
compositions of the individual terpene lactones (Figure 4)
and flavonol glycosides (Figure 2) even though the total
amounts for both components were more comparable
to the NIST SRMs (Table 6). It is also clear that the
Ginkgo products in liquid forms (sample F and sample G)
contain less terpene lactones and flavonols as compared
with commercial samples in the solid forms and the SRM
3247. Neither sample F nor sample G is a clear solution
and sample G contains large quantities of black-brown
solids. Extraction of the solids with MeOH/H 2O (1:1)
did not produce any flavonol or terpene lactone peaks. It
is reported that the liquid form of Echinacea purpurea
commercial products contains much less active ingredient (cichoric acid) compared to the solid form (19,20).
These findings raised concerns for the qualities of the
commercial liquid herbal extracts in general. More studies certainly are needed on this subject.
The differences between the NIST SRMs and the
commercial products, with respect to the percentiles of
individual flavonols and terpene lactones, may be due to
the quality, origin and maturities of the Ginkgo leaves,
and/or the extraction/purification/standardization procedures used by manufacturers. It is difficult to speculate

Time (min)

Relative absorbance

RT: 5.00 - 25.00

100
90
80
70
60
50
40
30
20
10
0

Kaempferol
Quercetin

NL:
2.12E4
Channel A
UV
srm324703

Isorhamnetin

100%
80%
60%
40%
20%

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

0%

Time (min)

Figure 3 LC/UV/MS chromatograms of NIST SRM 3247 after
the acid hydrolysis (Top: MS chromatogram; Bottom: LC/UV
chromatogram at UV 370 nm; GA, GB, GC standard for ginkgolide
A, B, and C).

SRM
3247

S-a

S-b

Bilobalide

S-c
Ginkgo A

S-d

S-e

Ginkgo B

S-f

S-g

Ginkgo C

Figure 4. Terpene lactone composition of commercial G. Biloba
products and the NIST SRM 3247.

Table 5. The LODs, the LOQs, the ranges, and the correlation coefficients of the LC/UV/MS method

MS

UV

Limit of detection (ng)

Limit of quantitaion (ng)

Range (µg/mL) 5 µg/inj.

Correlation coefficient r2

Bilobalide

0.080

0.250

0.054-20.000

0.9975

Ginkgo A

0.005

0.015

0.003-5.000

0.9963

Ginkgo B

0.020

0.060

0.013-10.000

0.9967

Ginkgo C

0.015

0.050

0.010-10.000

0.9910

Quercetin

0.010

0.030

0.008-20.000

0.9196

Kaempferol

0.005

0.015

0.005-10.000

0.9896

Isorhamnetin

0.065

0.200

0.043-25.000

0.9801

Quercetin

0.010

0.030

0.007-20.000

0.9927

Kaempferol

0.010

0.030

0.007-10.000

0.9988

Isorhamnetin

0.060

0.200

0.039-25.000

0.9914
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Table 6. The quantitative results of terpene lactones and flavonol aglyconesa,b,c
Bilobalide

Ginkgo A

Ginkgo B

Ginkgo C

Quercetin

Kaempferol

Isorhamnetin

Spl Conc (µg/mL)

2.23 ± 0.10

3.06 ± 0.18

1.62 ± 0.07

1.14 ± 0.06

2.00 ± 0.04

2.35 ± 0.07

2.63 ± 0.04

Daily intake (mg)

2.67 ± 0.11

3.68 ± 0.02

1.94 ± 0.08

1.37 ± 0.07

2.40 ± 0.04

2.82 ± 0.09

3.15 ± 0.09

Spl Conc (µg/mL)

2.00 ± 0.03

2.06 ± 0.04

1.48 ± 0.036

1.06 ± 0.030

2.57 ± 0.01

1.90 ± 0.02

2.45 ± 0.06

Daily intake (mg)

3.20 ± 0.05

3.29 ± 0.07

2.36 ± 0.06

1.69 ± 0.05

4.11 ± 0.02

3.04 ± 0.03

3.92 ± 0.09

Spl Conc (µg/mL)

2.31 ± 0.05

2.34 ± 0.04

1.54 ± 0.04

1.94 ± 0.11

6.59 ± 0.09

1.69 ± 0.05

2.91 ± 0.05

Daily intake (mg)

1.85 ± 0.04

1.87 ± 0.03

1.23 ± 0.03

1.55 ± 0.09

5.27 ± 0.07

1.35 ± 0.04

2.33 ± 0.04

Spl Conc (µg/mL)

2.92 ± 0.16

3.90 ± 0.09

2.59 ± 0.12

1.99 ± 0.04

5.40 ± 0.01

3.68 ± 0.04

5.45 ± 0.02

Sample
Sample A

Sample B
Sample C
Sample D
Sample E
Sample F
Sample G
SRM 3247

Daily intake (mg)

2.33 ± 0.13

3.12 ± 0.07

2.07 ± 0.10

1.59 ± 0.03

4.32 ± 0.01

2.95 ± 0.03

4.36 ± 0.01

Spl Conc (µg/mL)

4.98 ± 0.14

7.71 ± 0.24

3.49 ± 0.01

3.11 ± 0.02

7.77 ± 0.04

2.65 ± 0.23

3.55 ± 0.13

Daily intake (mg)

1.99 ± 0.06

3.08 ± 0.10

1.40 ± 0.01

1.25 ± 0.09

3.11 ± 0.17

1.06 ± 0.09

1.42 ± 0.05

Spl Conc (µg/mL)

0.74 ± 0.01

1.10 ± 0.05

0.50 ± 0.01

0.88 ± 0.03

2.69 ± 0.02

2.33 ± 0.01

6.72 ± 0.18

Daily intake (mg)

0.11 ± 0.01

0.16 ± 0.01

0.08 ± 0.01

0.13 ± 0.01

0.41 ± 0.01

0.35 ± 0.01

1.01 ± 0.03

Spl Conc (µg/mL)

1.11 ± 0.01

0.86 ± 0.046

0.64 ± 0.01

0.85 ± 0.03

10.22 ± 0.02

10.26 ± 0.01

25.25 ± 0.17

Daily intake (mg)

0.11 ± 0.01

0.09 ± 0.01

0.06 ± 0.01

0.09 ± 0.05

1.02 ± 0.01

1.03 ± 0.01

2.53 ± 0.02

Spl Conc (µg/mL)

2.64 ± 0.08

1.31 ± 0.01

0.83 ± 0.04

1.51 ± 0.02

3.04 ± 0.02

3.03 ± 0.06

4.22 ± 0.07

Daily intake (mg)

3.17 ± 0.09

1.57 ± 0.01

1.00 ± 0.04

1.82 ± 0.02

3.65 ± 0.02

3.64 ± 0.07

5.07 ± 0.09

a

Spl Conc (sample concentration) is the concentration (µg/mL) of the injected sample measured by the LC/UV/MS method, n = 3.
b
Daily intake are the daily intake value (mg) of a sample calculated from measured concentration and standardized for the label suggested
daily dosage.

Table 7. Total terpene lactones and flavonol contents of the investigated samplesa
Terpene lactones (mg)
Sample

a

Total flavonol
glycosides (mg)

Measured

Labeled

Measured

Labeled

Sample A

9.66

N/A

21.01

28.8

Sample B

10.55

N/A

27.73

28.8

Sample C

6.49

N/A

22.37

28.8

Sample D

9.12

N/A

29.04

28.8

Sample E

7.72

7.20

14.00

28.8

Sample F

0.48

N/A

4.34

N/A

Sample G

0.35

N/A

11.33

N/A

SRM 3247

7.56

N/A

30.89

N/A

 tandardized for the labeled suggested daily dosage (equivalent to
S
120 mg GBE where applicable, n = 3).

further about the differences because the normal range
of composition for these components is not k nown.
The SRMs represent a high quality, authentic, and well
homogenized samples produced from a single harvest in
a single season. It does not provide, nor is it intended to
provide, any information about the seasonal or processing variation. Characterization of the origin or processing of the G. Biloba material would be more accurate if
more plant components were taken into account. From a
limited number of commercial samples investigated, the
composition of flavonol glycosides can vary significantly
even though the total flavonol content is similar except

for sample C, sample E and the liquid samples. In the
cases of sample C and sample E, the percentiles of rutin
were dramatically higher compared to the others. An
article, “Code of Ethics & Business Conduct”, recently
released by the American Herbal Products Association(21)
has suggested that manufacturers may adulterate GBE
with rutin or quercetin to claim a higher total f lavonol
content to meet the standard set by Egb761®. While we
could not claim that sample C and sample E were adulterated solely based on the data in this study, it is clear that
the analysis of intact flavonol glycosides is necessary to
ensure the quality of the G. Biloba products and a more
detailed standard other than 24% total flavonols should
be applied. Thus, the current labeling practice of listing
only the total flavonol glycoside percentage may not be
adequate. The compositions of the f lavonol glycosides
may be a critical indicator of the quality of the G. Biloba
products. Establishing a normal range of the composition (flavonol glycosides and terpene lactones) would be
very useful in examining the authenticity and/or quality
of G. Biloba product. The study showed the qualities of
G. Biloba dietary supplements sold in the United States
were inconsistent at best and the NIST SRMs provided
a well-recognized authentic measurement tool to assess
the quality of G. Biloba dietary supplements.
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